



(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 31/58* (2006.01)
A61K 31/4375 (2006.01) *A61P 35/00* (2006.01)
A61K 31/573 (2006.01) *A61P 35/04* (2006.01)

(21) International Application Number:

PCT/EP2023/059123

(22) International Filing Date:

06 April 2023 (06.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/362,614 07 April 2022 (07.04.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).(72) Inventors: **COSULICH, Sabina Chiara**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge Cam-
bridgeshire CB2 0AA (GB). **BROWN, Jessica S**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge Cam-
bridgeshire CB2 0AA (GB). **ALBERTELLA, Mark R**;
ASTRAZENECA UK LIMITED, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge Cam-

bridgeshire CB2 0AA (GB). **LEO, Elisabetta**; AS-
TRAZENECA UK LIMITED, 1 Francis Crick Ave-
nue, Cambridge Biomedical Campus, Cambridge Cam-
bridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Association 813, Eastbrook House, Shaftesbury Road,
Cambridge Cambridgeshire CB2 8BF (GB).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: COMBINATION THERAPY FOR TREATING CANCER

(57) Abstract: The present disclosure includes methods, pharmaceutical compositions, and kits for the treatment of prostate cancer, wherein AZD5305 and abiraterone acetate are dosed in combination to a subject in need.




Fig. 1A




Fig. 1B

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*